all-cis-docosa-4,7,10,13,16,19-hexaenoic acid/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases necrotising enterocolitis incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Confirmed NEC was lower in infants from the DHA-group compared with the control-group (0/100 vs. 7/100, p = 0.007) with a RR of 0.93 (95% CI 0.881 to 0.981, p = 0.008); there was a risk difference of −7% (95% CI −12.00 to −1.99), and a number needed to treat of 15 (95% CI 8.3 to 50).”
Quoted verbatim from Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial.. - Study
- RCT
- Duration
- 14 days
- Dose
- 75 mg DHA/kg body weight daily for 14 days from the first enteral feed
- Population
- Preterm infants (birthweight 1000-1500 g) dosed enterally by orogastric tube; outcome measured in the same infants; per-protocol analysis; confirmed NEC defined as Bell stage IIa or greater (modified Walsh)
Effect 0.93 risk ratio, 95% CI 0.881 to 0.981
Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial.2021PMID:33671220An author is affiliated with a producerPermalink
Keep reading
- Everything the graph holds on all-cis-docosa-4,7,10,13,16,19-hexaenoic acid
- Every compound studied against Necrotising enterocolitis incidence
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PH2E8VXYEBFBW99891YC8K